Company Overview of Galenika a.d.
Galenika a.d. manufactures and markets pharmaceutical products in Europe, Asia, and Africa. It offers generic medicines and drugs, pharmaceutical raw materials, parapharmaceuticals, dietetic supplements, medical devices, and dental products; and contract manufacturing and laboratory services. The company provides its products in the form of tablets, capsules, units of sterile preparations, bottles of syrups and powders for oral suspensions, medicinal ointments and preparations for local applications, and dressings. It offers its products through representative offices and affiliates in Novi Sad, Niš, and Kragujevac, Serbia; Banjaluka and Sarajevo, Bosna and Hercegovina; Macedonia; Montenegro...
Batajnièki drum bb
Founded in 1945
Key Executives for Galenika a.d.
Compensation as of Fiscal Year 2016.
Galenika a.d. Key Developments
Serbia Cancels Sale Of Galenika As Talks With British-Russian Consortium Fail
Mar 10 17
Serbia's government has cancelled a procedure for the privatisation of Galenika a.d. Serbia's government has cancelled a procedure for the privatisation of Galenika at the proposal of a commission that held negotiations with the only bidder, a British-Russian consortium, government documents showed. "The privatisation process of Galenika via a strategic partnership model has been declared unsuccessful," the government said in a document. The government was looking to find a strategic partner in Galenika by a launching a tender for a 25% stake in the company for a minimum of €7 million. The British-Russian consortium was the only bidder left in the race after the bids submitted by EMS S.A., Cadila Pharmaceuticals Limited were rejected over procedural flaws.
A British-Russian Consortium Mulls Acquisition Of 25% Stake In Galenika
Feb 14 17
A British-Russian consortium is seeking acquisition of 25% stake in Galenika a.d. A British-Russian consortium said on February 14, 2017, that they are close to an agreement for the purchase of 25% of Galenika. The consortium comprising Frontier Pharma Limited and Russian LLC NPA Petrovax Pharm aims to transform Galenika into a regional pharmaceutical leader and plans to invest up to €30 million ($31.8 million) in quality improvements, technological upgrades and new product development which will allow the company to deliver high-quality and affordable products, it told SeeNews in an e-mailed statement. Banks are supportive of a deal with Frontier Pharma and NPA Petrovax Pharm and they expressed their support to Serbia's economy ministry on February 13, 2017, so there are no hurdles for the deal to be completed in the next two or three weeks, the consortium added. "Of all the options currently available to Galenika, a transaction with the consortium is by far the best alternative for the long-term sustainability and growth of Galenika. We look forward to continuing our productive discussions with the Republic of Serbia and being given the opportunity to transform Galenika into a world-class pharmaceutical company," the consortium added. The potential buyer has reportedly offered €7 million for the 25% shareholding interest.
Galenika Received Bids From 3 Companies
Aug 1 16
Galenika a.d. received bids for sale of 25% stake. Bidders include Cadila Pharmaceuticals Limited, EMS S.A., Frontier Pharma Limited, NPO Petrovax Pharm LLC. The bids will be opened on Friday, July 29, 2016, the ministry said in a statement. The bids will be ranked according to the number of jobs proposed and the plans for recapitalization of the company as the two most important criteria, the statement reads. The government will then announce the best bidder and it will have up to 90 days to negotiate a final deal with it.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|